BriaCell Therapeutics Corp.
BCTX
$3.18
-$0.09-2.75%
NASDAQ
| 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.60M | 1.60M | 1.55M | 1.68M | 1.68M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.17M | 5.15M | 5.77M | 9.23M | 9.83M |
| Operating Income | -7.17M | -5.15M | -5.77M | -9.23M | -9.83M |
| Income Before Tax | -6.34M | -5.83M | -1.25M | 1.69M | -11.33M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -6.34M | -5.83M | -1.25M | 1.69M | -11.33M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 46.40K | 27.10K | 34.60K | 23.50K | 39.30K |
| Net Income | -6.29M | -5.80M | -1.21M | 1.72M | -11.29M |
| EBIT | -7.17M | -5.15M | -5.77M | -9.23M | -9.83M |
| EBITDA | -7.14M | -5.13M | -5.70M | -9.23M | -9.83M |
| EPS Basic | -2.33 | -3.27 | -1.02 | 1.61 | -10.60 |
| Normalized Basic EPS | -1.45 | -2.04 | -0.63 | 1.01 | -6.61 |
| EPS Diluted | -2.33 | -3.30 | -1.07 | 1.61 | -10.60 |
| Normalized Diluted EPS | -1.45 | -2.04 | -0.63 | 1.01 | -6.61 |
| Average Basic Shares Outstanding | 2.70M | 1.78M | 1.19M | 1.07M | 1.07M |
| Average Diluted Shares Outstanding | 2.70M | 1.78M | 1.19M | 1.07M | 1.07M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |